Personal experimentation within reasonable parameters reveals optimal individual approaches

Key findings: People who received retatrutide at doses ranging from 1 mg to 12 mg experienced significant weight loss compared to the placebo group At 24 weeks, the percentage change in body weight ranged from -7.2% in the 1 mg group to -17.5% in the 12 mg group, compared to -1.6% in the placebo group At 48 weeks, the percentage change in body weight ranged from -8.7% in the 1 mg group to -24.2% in the 12 mg group, compared to -2.1% in the placebo group A large proportion of people receiving retatrutide (64% to 100%) achieved a weight reduction of 5% or more, with some participants even losing 30% or more of their baseline weight Retatrutide treatment showed improvements in cardiometabolic measures, including reductions in glycated haemoglobin (HbA1c), fasting glucose, insulin, blood pressure, and lipid levels Safety and tolerability The safety profile was generally favourable, with the most common side effects of retatrutide being mild to moderate gastrointestinal issues, such as nausea, vomiting, diarrhoea, and constipation

Why Seeing a Specialist Can Help If you are thinking about GLP-1 treatment in France, it is a good idea to ask your GP for a referral to an obesity specialist or centre
Your prescribing physician will determine the right schedule based on your health profile and goals
Does PlexusDx offer tirzepatide without weekly injections